Real World Evidence

Healthcare Professional Feedback on Proposed Standards for Presentation of RWE in Drug Advertising Directed to Health Professionals



Contents

1
2
3
6
16
22



Executive Summary

In May 2023, the Pharmaceutical Advertising Advisory Board (PAAB) initiated research with Healthcare Professionals, looking to solicit expert opinion regarding the proposed incorporation of Real-World Evidence (RWE) into drug advertising.

Those who successfully passed screening were invited to complete a 29 question online survey made up of quantitative and qualitative questions.



- A total of 60 healthcare professionals successfully completed the survey.
- While the initial objective was to gather responses from 100 doctors, the research was concluded upon reaching 60 participants. This decision was informed by the consistent responses received, indicating a saturation of opinions and diminishing the necessity to pursue the remaining 40 participants.
- The majority of respondents exhibited a consistent agreement in both the value and proposed presentation of Real World Evidence in Canadian drug advertising.

Methodology

In May 2023, the Pharmaceutical Advertising Advisory Board (PAAB) initiated a systematic recruitment and screening process aimed at healthcare professionals within Canada. The objective was to solicit their expert opinions regarding the proposed incorporation of Real-World Evidence (RWE) into pharmaceutical advertising.

Eligible participants, having successfully undergone the screening process, were provided with the draft guidance document elucidating the rationale behind the introduction of RWE. Subsequent to their review of this material, these professionals were prompted to participate in a structured online survey. This survey encompassed both quantitative and qualitative research questions to ensure a holistic understanding of their perspectives.

Those who successfully completed the online survey were provided with \$100 CAD digital gift card honoraria for their services.

Demographics

The research survey engaged 60 healthcare professionals, reflecting diversity in hospitals, practices, and specialties. Participants hail from across Canada, including British Columbia, Alberta, Ontario and Quebec. Moreover, the participant pool covers a spectrum of medical specialties, with the notable majority (20%) in Oncology.



*full list of institutions in Appendix 1

Demographics

Specialty



Oncology 19.64%

General Medicine 8.93%

Ophthalmology 8.93%

Pharmacy 8.93%

Family Medicine /Medicine 7.14%

Emergency Medicine 5.36%

Speciality	% of Total
Cardiology	3.57%
Clinical Research	3.57%
Family Physician	3.57%
Mental Health	3.57%
Paediatrics	3.57%
Public Health	3.57%
Geriatrics	1.79%
Hematopathology	1.79%
Immunology	1.79%
Lifestyle Medicine & Aesthetic Medicine	1.79%
Neurogastroenterology	1.79%
Neurology/Neurosciences/Cardiovascular	1.79%
Neurophysiology	1.79%
Neuropsychology	1.79%
Obstetrics & Gynecologist	1.79%
Physical Medicine and Rehabilitation	1.79%
Rheumatology	1.79%

Demographics



Region	% of Total
Ontario	62.26%
Quebec	16.98%
British Columbia	9.43%
Alberta	3.77%
Manitoba	3.77%
Saskatchewan	3.77%



RWE Visual Presentation



RWE Visual Presentation

Based on the draft guidance document you just viewed, please let us know if:

The visual cues (icon, grey call out box, limitation copy) will help you easily differentiate between gold-standard evidence and RWE presentations.

(60 out of 60 people answered this question)





Thematic analysis identified 3 themes noted below. Overall, respondents felt that the presentation of RWE could be easily differentiated from RCTs in this format.

Theme 1: There Is Effective Visual Differentiation. N = 12

Many doctors appreciated the use of visual elements like colours and boxes which helped them differentiate and focus on key areas of the content, making it visually engaging and easy to separate.

"The three elements used to identify the level of evidence are well easily recognizable."

Theme 2: Clarity of Content Presentation. N = 10

The presentation of the content was found to be clear and concise by several respondents. They felt that the layout, item order, and overall content structure were pertinent and effective in conveying the intended message.

"The presentation and language of this information make it very easy to find and dissect current study data on a product."

Theme 3: Effective Attention Draw and Highlights. N = 8

Several doctors felt that specific design elements, such as the use of a box or certain icons effectively drew their attention to key areas, ensuring that crucial data wouldn't be missed even in a quick scan.

EXAMPLE OF POSTCARD FORMAT

oriaMax[™] was 70.0% vs. xe: 29%, 95% CI: 17.3-37.8,

BRAND

Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with 41.0% with Psoriatal^m at Week 16 (treatment cliffe 001: Broyladav^m: n=198: Psoriatal^m: n=197; p

The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Monograph.

PASI Findings in the OASIS3 Severe Psoriasis Study ents in the PsoriaMax[™] 80 mg BID arm the Psoriak[™] 100mg OD arm (p=0.001) ents in the PsoriaMax[™] 80 mg BID arm the Psoriak[™] 100 mg OD arm (p=0.02) week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaM mg BID arm was 6.2 vs 8.2 in the PsoriaMax^m 80 mg BID arm (o=0.001)

PAAB

"The grey box draws your eye in - the ! alerts you to the type of study used and the text at the bottom of the results extrapolate the 'caveat' to reviewing the findings, all while not crowding the grey box and overwhelming the eye.

RWE Visual Presentation

The following explanatory statement will accompany the RWE presentation: "The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomised controlled trial or in the Product Monograph.

The inclusion of this explanatory statement will be a useful consideration when looking at data provided in advertising material.

(60 out of 60 people answered this question)





The statement in the grey box adds a layer of clarity and transparency by differentiating real-world data from randomized controlled trials and the Product Monograph, allowing clinicians to make more informed judgments.

Theme 1: Educational & Reminder Value. N = 7

The statement not only informs but also educates and reminds clinicians about the levels and quality of evidence. The verbatim indicates that the statement has an educational value, serving as a reminder of evidence quality, especially beneficial for medical professionals.

"For the non-experienced clinician, ie nurse or PA, there needs to be a bit more explanation because I don't believe they understand the nuance between different types of studies."

Theme 2: Design & Visualization Improvements. N = 6

Doctors suggest that while the statement is valuable, enhancing visual elements like the font size, colours, or inclusion of a graphical representation could offer a quicker and more effective comprehension of the evidence levels. While doctors appreciate the transparency of the statement, there are suggestions for improvements in design and visualization, such as clearer lettering, colour coding, and graphical representation to enhance understanding.

"Considering the level of evidence should have some kind of colour identifier to differentiate between RCTs and observational studies for example."

Theme 3: Clarity & Transparency. N = 5

EXAMPLE OF POSTCARD FORMAT

BRAND

Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax[®] was 70.0% vs. 41.0% with Psoriata[®] at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; or 0.01: PsoriaMax[®] or 158°. Recrist 118° or 129°, redmark and depicit).

The data in this grey box is from an observational study. It should be into cautiously as it is not a randomized controlled trial or in the Product More

PASI Findings in the OASIS3 Severe Psoriasis Study end, at week 24: tients in the PsorialMax[®] 80 mg BID arm attained PASI 90 vs 63% of the Psoriak*® 100mg OD arm (p<0.001) bents in the Psoriak*® 90 mg BID arm attained PASI 100 vs 55% of the Psoriak*® 100 mg OD arm (p=0.02)

At week 24, the average Dermatolog Life Quality Index (DLQI) in the PsoriaMax[®] 80 mg BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 mg BID arm (p<0.001)

PAAB

The verbatim consistently indicates that doctors value clear labelling and transparency about the quality and type of evidence provided, as it helps them interpret the data correctly.

"Yes, I think this helps quickly to identify the way in which the evidence should be interpreted."

EXAMPLE OF POSTCARD FORMAT **RWE Visual Presentation** Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax[®] was 70.0% vs. 41.0% with Psoriatal[®] at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Meongraph. The image is highlighting the key limitations of the RWE study. PASI Findings in the OASIS3 Severe Psoriasis Study he study's end, at week 24: IV of patients in the PoroiAMa[™] 800 mg BID arm attained PASI 90 vs 63% attents in the PoroiAM[™] 100mg CO arm (p=0.001) 0% of patients in the PoroiAMa[™] 800 mg BID arm attained PASI 100 vs 55 attents in the PoroiAM[™] 100 mg CO arm (p=0.02) eek 24, the average Dermatoly Life Quality Index (DLQI) in the PsoriAMa[™] BID arm was 62 vs 82 in the PsoriAMa[™] 80 mg BID arm (p=0.001) tained PASI 100 vs 55% It is important to me that the key limitations of the RWE studies are presented prominently. PAAB BRAND (60 out of 60 people answered this question) 1.7% 1.7% 6.7% 28.3% 61.7% 1 1 4 17 37 resp. resp. resp. resp. resp. 5 1 2 3 Δ Strongly disagree Neither agree or disagree Strongly agree



Participants perceived the image as effectively underscoring the constraints of RWE. While they expressed favourable opinions towards the present proposal, they also offered additional suggestions for enhanced support.

Theme 1: Presentation & Accessibility. N = 18

Respondents highlighted the need for the information to be presented in a manner that's easily accessible and understandable, even for those with varying degrees of healthcare knowledge. This includes suggestions on font size, formatting, and the use of clear language.

"It is important to have ready access to study limitation, however, make sure the language is readily understood by those with varying degrees of healthcare/study knowledge."

Theme 2: Clinical Relevance & Decision-Making. N = 8

Respondents consistently mentioned that having a clear summary of the limitations aids in their decision-making, especially in time-constrained clinical scenarios. Presenting the limitations directly influences clinicians' decisionmaking process by allowing them to quickly discern the study's relevance and applicability to their specific patient population.

"In clinical practice, you often do not have sufficient time to read through the entire study. The summary highlighted at the top is essential to gathering the key points in decision making."

Theme 3: Transparency & Trustworthiness N = 6

Respondents emphasized the importance of making readers aware of study limitations to ensure that they can trust the data, understand its applicability, and assess its relevance to clinical practice. Outlining the limitations of a study will provide the necessary transparency to clinicians and ensure trustworthiness of the presented data.

"It is important to report these limitations because it provides transparency and allows readers to understand the potential constraints and weaknesses of the study's findings."

RWE Visual Presentation Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax^{IIII} was 70.0% vs. 41.0% with Psoriata^{IIII} at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; 0 lata in this grey box is from an observational study. It should be interpreted ously as it is not a randomized controlled trial or in the Product Monograph. The prominent positioning of the icon within the grey box will PASI Findings in the OASIS3 Severe Psoriasis Study be a helpful reminder that the associated content should be send, at week 24: itients in the PsoriaMax[®] 80 mg BID arm attained PASI 90 vs 63% of n the Psoriak[®] 100mg OD arm (s-0.001) uitents in the PsoriaMax[®] 80 mg BID arm attained PASI 100 vs 55% of n the Psoriak[®] 100 mg OD arm (p=0.02) By the study's end 81% of patients patients in the 70% of patients interpreted with care and caution. patients in the Psoriak[®] 100 mg OD arm (p=0.04) At week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaMax[®] 80 mg BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 mg BID arm (p=0.001) PAAB BRAND (60 out of 60 people answered this question) 3.3% 3.3% 13.3% 23.3% 56.7% 2 2 8 14 34 resp. resp. resp. resp. resp. 5 1 2 3 Δ Strongly disagree Neither agree or disagree Strongly agree



Participants felt that the icon effectively grabs attention due to its design and therefore would be an effective symbol for this purpose. Further feedback suggests improvements in colour differentiation

Theme 1: Visual Attractiveness & Attention-Grabbing Capability N = 9

The icon effectively captures attention due to its prominence and its nature as a visual cue. A majority of the respondents feel that the icon, whether due to its size, placement, or nature, stands out and successfully draws the reader's attention.

"The icon always catches people's attention more."

Theme 2: Feedback on Colour & **Differentiation N = 8**

While the icon attracts attention, there is room for improvement in terms of colour contrast and differentiation from surrounding content. Many respondents suggest enhancing the colour or positioning of the icon to make it more discernible, especially if its intention is to draw the HCPs attention to the study limitations.

"The colour of the icon matches that of the top of the page, so isn't that differentiated. If it's truly cautionary (which it is), I recommended a colour that reflects that more e.g. red."

Theme 3: Universality & Interpretation of the Symbol N = 6

EXAMPLE OF POSTCARD FORMAT

The exclamation mark as a symbol is largely seen as universal, but there are varying opinions on its clarity for conveying the intended message.

"Does not really symbolize care or caution but more like it commands attention"

"I think the ! symbol is quite universal as a "hey there! hold up! read me!""

RWE Visual Presentation



RWE Visual Presentation

Please rank the icons in order of your preference.

1 being your favourite, 3 being your least.

Participants ranked the icons in order of preference as noted below:



Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax^{IIII} was 70.0% vs. 41.0% with Psoriata^{IIII} at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; or 0.01: PsorialMax^{IIII} or 158°. Receivat MIII: on 157°. release an endocida 11. The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Monograph. Based on the collective measures being proposed, PASI Findings in the OASIS3 Severe Psoriasis Study I can easily identify information that should be interpreted send, at week 24: tients in the PsorialMax[®] 80 mg BID arm attained PASI 90 vs 63% of the Psoriak*® 100mg OD arm (p<0.001) bents in the Psoriak*® 90 mg BID arm attained PASI 100 vs 55% of the Psoriak*® 100 mg OD arm (p=0.02) with care and caution. At week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaMax[®] 80 ms BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 ms BID arm (p<0.001) PAAB BRAND (60 out of 60 people answered this question) 0% 3.3% 11.7% 50% 35% 021resp. 0 2 7 30 resp. resp. resp. resp. Avg. 4.2 1 2 3 5 Δ Strongly disagree Neither agree or disagree Strongly agree

RWE Visual Presentation



Participants indicated that the aggregate measures facilitated the necessary caution for the examination of the content. They further emphasized the efficacy of the specific elements and their synergistic combination, while also providing suggestions for subsequent refinements.

Theme 1: Effective Visual Differentiation. N = 7

Visual cues, like shading, icons, and distinct boxes, enable better distinction of important information. Several doctors appreciate how visual differentiation, whether through icons, boxes, or shading, distinguishes the critical content from other parts of the advertisement. This distinction allows them to readily identify the content requiring careful interpretation.

"Everything in the "box" looks different from the rest of the page."

Theme 2:Suggested Enhancements for Improved Clarity. N = 8

Doctors recommend certain enhancements like selective bolding, colour changes, and font differentiation to ensure critical content is highlighted effectively. While the doctors acknowledge the advertisement's effectiveness, they also provide constructive feedback on areas of improvement, particularly around font, text size, and colour to further emphasize the critical data.

"I actually think that the 1st sentence of section 3 should be bolded and in the same text as the "!" statement."

Theme 3: Recognition of Comprehensive Design Elements. N = 6

EXAMPLE OF POSTCARD FORMAT

Doctors acknowledge the combination of design elements, including icons, text size, shading, and explanatory notes, work together to emphasize important content. Several comments underline a broad recognition of the multifaceted design approach in the advertisement, including shading, highlighting, and larger text, which collectively draws attention and aids in comprehension.

"I can easily identify information that should be interpreted with care and caution because the text is boxed, and the exclamation point icon is present."

EXAMPLE OF POSTCARD FORMAT **RWE Visual Presentation** Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax^{IIII} was 70.0% vs. 41.0% with Psoriata^{IIII} at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; or 0.01: PsorialMax^{IIII} or 158°. Receivat MIII: on 157°. release an endocida 11. The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Meongraph. Based on the collective measures being proposed, PASI Findings in the OASIS3 Severe Psoriasis Study end, at week 24: tients in the PsorialMax[®] 80 mg BID arm attained PASI 90 vs 63% of the Psoriak*® 100mg OD arm (p<0.001) bients in the Psoriak*® 90 mg BID arm attained PASI 100 vs 55% of the Psoriak*® 100 mg OD arm (p=0.02) I can quickly differentiate the types of content being presented At week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaMax[®] 80 ms BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 ms BID arm (p<0.001) and this is an important time saving consideration for me. PAAB BRAND (60 out of 60 people answered this question) 0% 3.3% 16.7% 40% 40% 0 2 10 24 24 resp. resp. resp. resp. resp. Avg. 4.2 5 1 2 3 Δ Strongly disagree Neither agree or disagree Strongly agree

Ę

Participants agreed that presenting the RWE data in this format enabled them to quickly differentiate RWE from gold standard RCT data.

Theme 1: Clarity and Conciseness of Presentation. N = 9

Doctors appreciate the clear and concise layout, which aids in quick information processing for clinical decision-making. Expansion on title: The majority of doctors appreciate the streamlined presentation of the advertisement. The clear and concise nature of the information helps them easily identify the relevant content, making it simpler to apply in their clinical decision-making.

"Information presented in a concise and well-constructed manner."

Theme 2: Effective Differentiation Through Design. N = 7

Design elements such as colour differentiation, font sizes, and distinct segments make the content readily distinguishable. Doctors recognize the use of various design elements that help in differentiating between different types of content. This differentiation is essential for them to quickly identify and understand the presented information.

"I can efficiently differentiate the types of content being presented due to the distinct presentation styles, such as boxed paragraphs, light backgrounds (including those within the box), and the logical item order."

Theme 3: Highlighted Critical Information for Quick Reference . N = 6

Doctors value the ability to immediately identify where the critical information lies, ensuring they're well-informed during decision-making. Many doctors pointed out that the advertisement effectively highlights essential details, allowing them to be better informed. Such features are especially valuable when doctors need to make quick clinical decisions based on the presented information.

Yes. This is very helpful to identify immediately where to read the critical information and what exactly I need to be aware of when applying the information to my clinical decision making."

RWE Base Requirements

2



Transparent RWE Disclosures Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax[®] was 70.0% vs. 41.0% with Psoriata[®] at Week 16 (treatment difference: 29%, 95% Ct: 17.3-37.8; or 0.01: PsoriaMax[®] or 158°. Recrist 118° or 129°, redmark and depicit). The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Monograph. The published paper contains sufficient methodologic PASI Findings in the OASIS3 Severe Psoriasis Study information, and clearly states the findings and any send, at week 24: tients in the PsorialMax[®] 80 mg BID arm attained PASI 90 vs 63% of the Psoriak*® 100mg OD arm (p<0.001) bents in the Psoriak*® 90 mg BID arm attained PASI 100 vs 55% of the Psoriak*® 100 mg OD arm (p=0.02) limitations of the methodology and findings. At week 24, the average Dermatolog Life Quality Index (DLQI) in the PsoriaMax 80 mg BID arm was 6.2 vs 8.2 in the PsoriaMax⁵⁶ 80 mg BID arm (p<0.001) BRAND (60 out of 60 people answered this question) 0% 8.3% 8.3% 41.7% 41.7% 0 5 5 25 25 resp. resp. resp. resp. resp. 1 2 3 5 Δ Strongly disagree Neither agree or disagree Strongly agree

Participants agreed that this presentation of RWE successfully states any limitations of the methodology.

Theme 1: Emphasis on Transparency & Completeness. N = 6

Doctors highlighted the importance of a complete and transparent presentation of study limitations, methodology, and findings for accurate application and criti cal for determining how to apply the knowledge to patient care effectively.

"...limitations were well mentioned, with bias of the study identified. This is important before applying knowledge to patient care.

Theme 2: Clarity & Conciseness of Information. N = 5

Doctors value clear, succinct, and easy-to-understand summaries of study specifics, which aid in guick understanding and decision-making. The doctors have highlighted the need for clear and concise information, particularly about the study type, sample size, and variables tested. This makes the data more digestible and aids in its effective application.

"Excellent succinct information about the type of study, how many people, variable being tested etc.

Theme 3: Importance of Knowledge Contextualization. N = 4

EXAMPLE OF POSTCARD FORMAT

Doctors emphasize the significance of understanding the broader context in which a study is conducted, including comparisons to other studies, for better comprehension and application. Some doctors noted that while they need clear findings and limitations from a single study, understanding how these findings fit within the larger body of evidence or relate to other studies is equally crucial.

"I need to know what kind of data I am working with in order to place a weight/significance on the new research to help guide decision making."

Transparent RWE Disclosures

The methodology is predefined in the publication, and any amendments to the methodology are clearly justified (e.g. required for additional scientific merit).

<text><image><image><section-header><section-header><section-header><list-item><list-item><text><text><text><text><text><text>

Superior skin clearance (PASI 100) demonstrated

EXAMPLE OF POSTCARD FORMAT

(60 out of 60 people answered this question)



Doctors agreed that this presentation of the methodology is clearly justified in the visual presentation.

Theme 1: Clarity & Presentation of Methodology. N = 7

Doctors emphasize the importance of having a clear, predefined, and well-presented methodology. This ensures that the research is unbiased, sound, can be critically assessed, and is easily understandable.

"It is important to disclose all details re methodology so that the reader can critically assess the data that are being presented to support a promo claim in the piece."

Theme 2: Application to Clinical Practice. N = 3

The methodology and the quality of research directly influence clinical decision-making. High-quality research is preferred as it provides more accurate and applicable insights for patient care.

"High quality research will always trump low quality research for clinical decision making."

Theme 3: Concerns about Changes & Bias. N = 4

Any changes to the predefined methodology can lead to misinterpretation of data and potential biases. Such changes need to be justified and examined with caution

"Changes to the methodology could also lead to misinterpretation of the data. If the changes and comments identify potential alternative benefits compared to the primary outcomes, the data needs to be reexamined with caution and would warrant further or another study to identify whether said changes were actually real."

Transparent RWE Disclosures

The data are collected from empirical observation (as opposed to sponsor-influenced modelling).

(60 out of 60 people answered this question)





The doctors' comments, emphasized the importance of unbiased data, the need for clarity in presentation, and the preference for empirical evidence over modelling.

Theme 1: Importance of Unbiased Data. N = 8

Doctors emphasize the criticality of unbiased data collection and interpretation. They believe that empirical evidence, as opposed to sponsor-influenced modelling, offers a more reliable and ethical approach to data analysis.

".....sponsors have their agenda & goals & ways to interpret data which may not always be beneficial or the exact truth."

Theme 2: Empirical Evidence Over Modelling. N = 6

There's a strong preference for empirical evidence over sponsor-influenced modelling. Doctors believe that empirical data, derived from real-world observations, is more valuable and trustworthy in scientific research.

"There is a place and use-cases for modelling, however empirical evidence is key."

Theme 3: Clarity & Presentation. N = 3

EXAMPLE OF POSTCARD FORMAT

BRAND

Superior skin dearance (PASI 100) demonstrated vs. Psoriatal[™] at Week 161 Week 160 Week 16

PASI Findings in the OASIS3 Severe Psoriasis Study

By the study's end, at week 24: a 81% of patients in the "portalitain" 80 mg 800 arm astained PASI 90 vs 63% of 70% of patients in the Portalitain" 80 mg 800 arm astained PASI 100 vs 55% of patients in the Portalit" 100 mg 00 arm (p-0.02) At week 24, the average Demonstroly Life Qualitained Ross (DLQ) in the Portalitain" for g800 arm was 20 vs 82 n the Portalitian" 80 mg 800 arm (p-0.00)

PAAB

Doctors highlight the need for clarity in the presentation of data and terms. Clear definitions and tables can enhance understanding and interpretation, ensuring that the data's significance is easily grasped.

"Needs to be put in table to make it easier for the reader to understand."

Transparent RWE Disclosures Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax^{IIII} was 70.0% vs. 41.0% with Psoriata^{IIII} at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; or 0.01: PsorialMax^{IIII} or 158°. Receivat MIII: on 157°. release an endocida 11. The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Monograph. It is important to know about currently available real-PASI Findings in the OASIS3 Severe Psoriasis Study world evidence. s end, at week 24: tients in the PsorialMax^{IM} 80 mg BID arm attained PASI 90 vs 63% of the Psoriak IM SorialMax^{IM} 80 mg BID arm attained PASI 100 vs 55% of the Psoriak IM 100 mg DD arm (p=0.02) At week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaMax[®] 80 ms BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 ms BID arm (p<0.001) PAAB BRAND (60 out of 60 people answered this question) 0% 0% 3.3% 30% 66.7% 0 0 2 18 40 resp. resp. resp. resp. resp. 2 5 1 3 Δ Strongly disagree Neither agree or disagree Strongly agree



Doctors value RWE for its ability to complement RCTs by offering broader insights, its role in gauging drug performance in real-world scenarios, and its presentation in easily digestible formats for quick reference and deeper exploration.

Theme 1: RWE as a Comprehensive & Complementary Tool to RCTs. N = 5

Doctors view RWE as a valuable supplement to randomized controlled trials (RCTs), offering insights that might not be captured in a controlled environment and providing a broader perspective, especially when RCTs might not be fully generalizable.

"RWE is sometimes all we have and it's important to acknowledge this. while understanding its limitations."

Theme 2: RWE's Role in **Understanding Drug Performance in** Real-World Settings. N = 6

Doctors emphasize the importance of RWE in understanding how drugs perform outside of clinical trials, especially when considering their effectiveness and potential side effects in diverse populations.

"It is vital to understand the expected performance of a drug in the real world, as drug effectiveness tends to decrease outside clinical trials."

Theme 3: Ease of Access & Digestibility of RWE. N = 4

EXAMPLE OF POSTCARD FORMAT

Doctors value the presentation of RWE in easily digestible formats, such as infographics, which allow for quick insights and further exploration if desired.

"There are so many new studies, new treatment options, etc., so when a mini-infographic is created that delivers a brief snapshot of a study, it is exciting as the new evidence is easily digested and if the clinician wants to read more about it, they can easily look up the study."

Transparent RWE Disclosures Superior skin clearance (PASI 100) demonstrated The percentage of patients achieving PASI 100 with PsoriaMax^{IIII} was 70.0% vs. 41.0% with Psoriata^{IIII} at Week 16 (treatment difference: 29%, 95% CI: 17.3-37.8; or 0.01: PsorialMax^{IIII} or 158°. Receivat MIII: on 157°. release an endocida 11. The data in this grey box is from an observational study. It should be interpreted cautiously as it is not a randomized controlled trial or in the Product Monograph. Real world evidence is useful to me in my practice. PASI Findings in the OASIS3 Severe Psoriasis Study s end, at week 24: tients in the PsorialMax¹⁰⁰ 80 mg BID arm attained PASI 90 vs 63% of the PsorialKa¹⁰⁰ 80 mg BD arm (s=0.001) tients in the PsorialMax¹⁰⁰ 80 mg BID arm attained PASI 100 vs 55% of the PsorialK¹⁰⁰ mg DD arm (s=0.02) At week 24, the average Dermatoloy Life Quality Index (DLQI) in the PsoriaMax[®] 80 ms BID arm was 6.2 vs 8.2 in the PsoriaMax[®] 80 ms BID arm (p<0.001) PAAB BRAND (60 out of 60 people answered this question) 0% 0% 8.3% 25% 66.7% 0 0 5 15 40 resp. resp. resp. resp. resp. 2 5 1 3 Δ Strongly disagree Neither agree or disagree Strongly agree



These themes capture the essence of the doctors' comments, emphasizing the realworld applicability of RWE, its role as a complement to controlled trials, its importance in evidence-based decision-making, and its ability to keep pace with current practice.

Theme 1: Real-World Applicability N = 5

Doctors value RWE because it reflects the realities of clinical practice. They believe that RWE provides insights that are directly applicable to real patients with genuine health concerns, making it more relevant than controlled trials in many scenarios.

Theme 2: Complement to Controlled Trials. N = 6

While randomized controlled trials (RCTs) are considered the gold standard, doctors appreciate RWE for capturing data not always evident in RCTs. They believe RWE offers a broader perspective, especially when certain populations are excluded from controlled studies.

Theme 3: Keeping Pace with Current Practices. N = 4

EXAMPLE OF POSTCARD FORMAT

Doctors highlight that RWE helps them stay updated with current practices, especially when guidelines lag behind. They believe RWE offers insights into medication tolerability, patient follow-up, and other evolving aspects of patient care.

"We live in the real world and have real patients with real diseases that need real meds."

"It is nice to know how likely is a treatment going to be effective, NNT, clinically significant results, new treatments with great results etc. This way if a patient asks about it, I can give them an evidence-based answer."

"Current guidelines are often behind on current practice which changes based on real-world evidence of medication tolerability, patient follow up etc."

Transparent RWE Disclosures

The addition of real world evidence that meets defined base requirements for evidence increases the utility and value of advertising.



(60 out of 60 people answered this question)



Doctors overall appreciate the value of Real World Evidence in drug advertising overall.

Theme 1: Reflective of Real-World Practice & Informed Decision Making. N = 10

Doctors appreciate RWE because it mirrors their actual practice experiences and provides additional insights beyond traditional data, aiding in more informed clinical decision-making.

"RWE is valuable as it offers additional information beyond what is normally reported in the Product Monograph and clinical investigation report, as it is commonly collected from a large number of individuals and diverse patient populations."

Theme 2: Enhanced Credibility & Trustworthiness. N = 5

Doctors believe that the inclusion of real-world evidence (RWE) in advertising can enhance the credibility and trustworthiness of the information presented.

"Real world evidence is key for any advertising."

Theme 3: Need for a Balanced View on RWE & Traditional Data. N = 3

While doctors recognize the value of RWE, they also emphasize the importance of not overshadowing gold standard data from trials.

"I would rather see gold standard data from trials than distracting/diluting RWE unless it is unique and truly fills a gap in our understanding of the trial data."

Appendix 1

Participants contributed from the following institutions:

BC Children's Hospital **Canadian Red Cross** CancerCare Manitoba CHUQ (Quebec Universirty...) CMPA Community Credit Valley Family Health Team **Cross Cancer Institute Dentistry On King** Dr Dallas Med Prof Corp Dr. Kingsley R. Lee Inc. First Town Dental fondation-de-l-ordre-des-dentistesdu-québec Fraser Health Authority Halton Healthcare Heartlake health centre Hotel-dieu de sherbrooke Luna Rx Pharmacy McGill University **McMaster** Medicine Hat Adult Addiction & Mental Health Clinic Neuroperforma

Niagara Health North Bay North York General Hospital North-eastern University College of Professional Studies Ottawa Department of Medicine Perceiv Al Princess Margaret Hospital/UHN Purposemed Region of Peel RI-MUHC - Glen site - Centre for Innovative Medicine **Royal Columbian** Southlake regional health centre Sunnybrook health science centre The Hospital for Sick Children The Neuro (Montreal Neurological Institute-Hospital) The Simkin Centre; Shared Health Manitoba University Health Network University of Saskatchewan University of Toronto Wascana rehabilitation

Thank You

